⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Table S1 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma

Kevin Christian Montecillo Gulay Xinlian Zhang Vasiliki Pantazopoulou Jay Patel Edgar Esparza Deepa Sheik Pran Babu Satoshi Ogawa Jonathan Weitz Isabella Ng Evangeline Mose Minya Pu Dannielle D. Engle Andrew M. Lowy Hervé Tiriac

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Table S1. List of drugs used in this study.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gulay et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db64358752321e https://doi.org/10.1158/0008-5472.27028369

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S1 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma2024
2Table S2 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma2024
3Table S2 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma2024
4Table S3 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma2024
5Table S3 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma2024

More related papers

Data from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma2024
Table S1 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines2022